Page 1

abbvie PRESS RELEASE AbbVie Reports Second - Quarter 2021 Financial Results Reports Second - Quarter Diluted EPS of $ 0.42 on a GAAP Basis ; Adjusted Diluted EPS of $ 3.11 Delivers Second - Quarter Net Revenues of $ 13.959 Billion , an Increase of 33.9 Percent on a Reported Basis Second - Quarter Global Net Revenues from the Immunology Portfolio Were $ 6.120 Billion , an Increase of 15.1 Percent on a Reported Basis , or 13.8 Percent on an Operational Basis ; U.S. Humira Net Revenues Were $ 4.257 Billion , an Increase of 7.1 Percent ; Internationally , Humira Net Revenues Were $ 811 Million , a Decrease of 6.0 Percent on a Reported Basis , or 12.6 Percent on an Operational Basis , Due to Biosimilar Competition ; Global Skyrizi Net Revenues Were $ 674 Million ; Global Rinvoq Net Revenues Were $ 378 Million ● ● ● ● Second - Quarter Global Net Revenues from the Hematologic Oncology Portfolio Were $ 1.816 Billion , an Increase of 14.1 Percent on a Reported Basis , or 13.2 Percent on an Operational Basis ; Global Imbruvica Net Revenues Were $ 1.381 Billion , an Increase of 7.2 Percent , with U.S. Net Revenues of $ 1.099 Billion and International Profit Sharing of $ 282 Million ; Global Venclexta Net Revenues Were $ 435 Million Second - Quarter Global Net Revenues from the Neuroscience Portfolio Were $ 1.459 Billion ; Global Botox Therapeutic Net Revenues Were $ 603 Million ; Global Vraylar Net Revenues Were $ 432 Million Second - Quarter Global Net Revenues from the Aesthetics Portfolio Were $ 1.434 Billion ; Global Botox Cosmetic Net Revenues Were $ 584 Million Updates 2021 GAAP Diluted EPS Guidance Range from $ 7.27 to $ 7.47 to $ 6.04 to $ 6.14 ; Raises 2021 Adjusted Diluted EPS Guidance Range from $ 12.37 to $ 12.57 to $ 12.52 to $ 12.62 NORTH CHICAGO , III . , July 30 , 2021 - AbbVie ( NYSE : ABBV ) announced financial results for the second quarter ended June 30 , 2021 . " AbbVie delivered another strong quarter and our business continues to perform extremely well across the portfolio , with AbbVie's new immunology assets contributing more than $ 1 billion of combined sales in the quarter , " said Richard A. Gonzalez , chairman and chief executive officer , AbbVie . " The Allergan integration also continues to track exceptionally well , with both the neuroscience and aesthetics portfolios delivering double - digit sequential growth . Based upon the momentum of our business , we are raising our full year 2021 EPS guidance and believe AbbVie is very well positioned for the long term . " Note : " Operational " comparisons are presented at constant currency rates and reflect comparative local currency net revenues at the prior year's foreign exchange rates . 1